



*Improving healthcare decisions*

<b>Chapter Name</b>	<b>Czech</b>
<b>President</b>	Jana Skoupá MD, Czechta Institute ops, Pod Šmukýřkou 2, 150 00 Prague; jana.skoupa@iol.cz
<b>President-Elect</b>	NA (president-elect resigned, new elections are being prepared)
<b>Past President</b>	Tomaš Doležal MD, iHETA, Václavská 12, 120 00 Prague; dolezal@iheta.org
<b>Secretary</b>	NA
<b>Treasurer</b>	Jana Skoupá MD, Czechta Institute ops, Pod Šmukýřkou 2, 150 00 Prague; jana.skoupa@iol.cz
<b>Director</b>	Jan Švihovec, Department of Pharmacology, Charles University Prague; jan.svihovec@lfmotol.cuni.cz
<b>Director</b>	Jiří Klimeš PharmDr, Novartis s.r.o, Prague; jiri.klimes@novartis.com
<b>Director</b>	Leoš Fuksa PharmDr, Sanofi s.r.o, Prague; leos.fuksa@sanofi.com
<b>Director</b>	Jan Hambalek Mgr, Novartis s.r.o, Prague; jan.hambalek@novartis.com
<b>When are elections held for your Chapter's Board?</b>	October 2016
<b>Regional Chapter Members - 2017</b>	170
<b>Regional Chapter Members - 2016</b>	169
<b>Notes re Chapter members</b>	
<b>Full ISPOR members (those paying dues to ISPOR Headquarters)</b>	20
<b>Does your Chapter collect membership dues or fees from individuals for local Chapter membership?</b>	15 euros
<b>Benefits Chapter offer to members</b>	Free access to HE data published by ISPOR Czech Chapter. Free participation in symposia, conferences and activities organized by the Czech ISPOR Chapter. Discounts on several other activities co-organized together with the ISPOR Czech Chapter.
<b>Chapter's accomplishments in 2017 with regard to membership recruitment, retention, and engagement.</b>	Due to high number of members, focus on retention.
<b>Academia%</b>	10
<b>Government/HTA Agency%</b>	10
<b>Industry - Pharmaceutical/Medical Device/Diagnostics/ Biotech%</b>	50
<b>Consulting%</b>	20
<b>Clinicians%</b>	10
<b>Student%</b>	
<b>Other%</b>	
<b>Chapter's accomplishments in 2017 with regard to education and training.</b>	Several training activities mainly among students to increase awareness in HE: Pharmaceutical Faculty Hradec Králové Pharmaceutical Faculty Brno Medical Faculty, Charles University Prague

<b>Chapter's accomplishments in 2017 with regard to research.</b>	Efforts to implement results of MCDA and comparative effectiveness working groups into HTA local assessment. Several HE presentations on national and international conferences.
<b>Chapter's accomplishments in 2017 with regard to policy-related activities.</b>	Cooperation on "orphan drugs" and their assessment in HTA.
<b>Chapter's accomplishments with regard to Chapter meetings, workshops, or conferences in 2017.</b>	Chapter meeting on Innovative drugs (spring 2017). Meeting on patient's involvement in HTA process, together with international experts (spring 2017). Participation on a number of conferences with specific HE aspects.
<b>Articles published in ISPOR's publication in 2017 - <i>Value in Health</i>, <i>Value in Health Regional Issues</i>, <i>Value and Outcomes Spotlight</i>, and ISPOR Regional newsletters by members in your Chapter.</b>	Skoupá J. Drug Policy in the Czech Republic. <i>Value Health Reg Issues</i> 2017;13:55–8.
<b>Contributions to ISPOR Conferences and Events by Chapter members in 2017. Include workshops, poster, and podium sessions.</b>	Several posters at the European conference 2017.
<b>Describe any regional patient engagement activities.</b>	Guidance on newly established patient organization, best practices.
<b>Activities organized for students or new professionals.</b>	Usually included in national and international activities.
<b>Chapter affiliations with any institutions, universities, government, or associations (other than ISPOR).</b>	Czech Medical Society
<b>Does your Chapter have any agreements of sponsorship arrangements with any for-profit companies, governments, health authorities, or associations?</b>	No
<b>Chapter (as a group, not as individual members) formal comments or responses to any government or health authority.</b>	No
<b>Chapter Groups</b>	Research
<b>HTA in your Chapter's country or region.</b>	Our country/region requires HTA , but the Chapter is not involved. Our country/region requires HTA and the Chapter participates in the development/update of national/regional HTA guidelines.
<b>Is your Chapter officially registered with regional authorities in your country?</b>	No
<b>Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?</b>	No
<b>Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?</b>	Yes
<b>Does the Chapter have a bank account?</b>	www.farmakoekonomika.cz Yes
<b>Official organizational email address?</b>	No
<b>How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?</b>	Creation/support to regional (e.g. CEE) working groups to solve regional/local issues and exchange best practices.
<b>3 challenges the Chapter is facing at the start of 2018.</b>	Legal changes and chapter involvement in adjustments, main focus on orphan drugs and temporarily reimbursed drugs. Separation of assessment and decision process in HTA (topic for discussions during 2018-2019)

**Current Chapter members.**  
**CV for the Chapter President.**  
**Chapter's Annual Work Plan.**  
**Who prepared this report.**  
**FCPA Agreement**

Patient organisation's support

Jana Skoupá\_CV\_1\_2017.doc

2018 Regional Chapter Annual Work Plan.pdf

Jana Skoupá, MD +420 602 24 87 13 jana.skoupa@iol.cz

x